ST Pharm Co., Ltd.

ST Pharm Co., Ltd.

ST Pharm Co., Ltd.

Overview
Date Founded

1983

Headquarters

#802, Siheunggongdan 1-Na,231 Hyeomnyeok-ro,Siheung, Gyeonggi 15086

Type of Company

Public

Employees (Worldwide)

466

Industries

Pharmaceuticals

Company Description

ST Pharm Co., Ltd. develops and manufactures pharmaceutical products. It operates throught the following business divisions: New Drug Contract Manufacturing Organization (CMO), Generic Active Pharmaceutical Ingredients (APIs), Fine Chemical, and Bio. The New Drug CMO business offers services such as process optimization, documentation support, and validation. The Generic APIs business produces APIs for anti-cancer, tubeculosis, coagulant, and fungal, asthma, diabetes mellitus, hepatitis B, and Epilepsy treating drugs. The Fine Chemical business offers pharmaceutical intermediates. The Bio business develops and produces ribonucleic acid therapeutics and phosphoamidite monomers. The company was founded in 1983 and is headquartered in Siheung, South Korea.

Paths to ST Pharm Co., Ltd.
Potential Connections via
Relationship Science
You
ST Pharm Co., Ltd.
Recent Transactions
Details Hidden

Dong-A Socio Holdings Co., Ltd. purchases ST Pharm Co., Ltd.

Details Hidden

Dong-A Socio Holdings Co., Ltd. purchases ST Pharm Co., Ltd. from Dong-A ST Co., Ltd.

Details Hidden

ST Pharm Co., Ltd. purchases Dong A St Co. Ltd. /Banwol Factory from Dong-A ST Co., Ltd.

Clients

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

Key Stats and Financials As of 2020
Market Capitalization
$1.29B
Total Enterprise Value
$457M
Earnings Per Share
$-0.65
Three Year Compounded Annual Growth Rate Of Revenue
-15.09%
Revenue
$107M
Net Profit
$-12.1M
Total Equity
$257M
Investments
Details Hidden

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in La Jolla, CA.

Investors
Details Hidden

Neoplux is a hands-on manager which invests in start-up and established companies and distressed companies across sectors. Their geographic focus is on Korea.The firm seeks to make selective investments in companies with strong growth potential which can secure independent and differentiated technologies and independent markets and which have an organic combination of corporate operations including development, production, sales and administration.Neoplux partners with their investee companies, seeking to increase value by supporting them mainly through mid and long-term strategic planning while nurturing their core capabilities so that they can continue to improve their bottom line.The firm typically holds investments for two to four years, exiting through IPOs, M&As, LBOs and trade sales.

Suppliers
Government of South Korea Government | Seoul, South Korea

Government of South Korea provides news about Korea, Korean government policy, information on Korean history, Korean culture, and traveling in South Korea. It is composed of executive, legislative, and judiciary branch, independent organizations, and local governments.

Mediplex Corp. Hospitals & Patient Services | Cheongju, South Korea

Mediplex Corp. develops medical device and engages in research and development of medical technologies. It offers multi-coated drug-eluting stent for antithrombosis and antirestenosis. The company was founded in October 7, 1998 and is headquartered in Cheongju-si, South Korea.

Competitors
Thermo Fisher Scientific, Inc. Industrial Machinery & Manufacturing - Waltham, Massachusetts

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Catalent, Inc. Pharmaceuticals - Somerset, NJ

Catalent, Inc. operates as a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale manufacturing of oral solid dose forms for pharmaceutical and consumer health markets, and supporting ancillary services. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing; formulation, development, and manufacturing for parenteral dose forms, which include prefilled syringes, vials, and cartridges; and analytical development and testing services for large molecules. The Oral and Speciality Delivery segment provides advanced formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by ST Pharm Co., Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of ST Pharm Co., Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and ST Pharm Co., Ltd..